A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans Abstract #386

Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Aim(s): We hypothesized that chronic PPI use would increase circulating plasma gastrin, CGA and pancreastatin levels.
Materials and methods: Thirty patients who used PPIs for six months or more (mean duration 3.1 ±2.5 years) and a separate control group of thirty patients who never used antacid medications were prospectively evaluated with plasma gastrin, CGA and pancreastatin determinations.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result